Company news
China Resources Double-Crane Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Announcement on Obtaining Drug Registration Certificate for Sodium Valproate Oral Solution by Holding Subsidiary Hunan Xiangzhong Pharmaceutical Co., Ltd.
March 17, 2026
Announcement on Convening the 2025 Annual Performance Briefing
March 12, 2026
Announcement on Implementing Repurchase and Cancellation under 2021 Restricted Stock Incentive Plan
March 11, 2026
Announcement on Wholly-owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Sodium Acetate Ringer's Injection
March 6, 2026
Announcement on Wholly-owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. Obtaining Drug Registration Certificate for Balanced Salt Irrigation Solution
February 26, 2026
Announcement on Drugs Being Selected for National Procurement Continuation After the Expiry of Agreement
February 10, 2026
Announcement on Resolutions of the 17th Meeting of the 10th Board of Directors
February 5, 2026
Announcement on Wholly-owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Compound Sodium Acetate Ringer's Injection
January 28, 2026
Announcement on Obtaining Approval from China Securities Regulatory Commission for the Public Issuance of Corporate Bonds to Professional Investors
January 26, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
January 23, 2026
Announcement on Obtaining Notice of Approval for Drug Supplementary Application for Pediatric Compound Amino Acid Injection (19AA-I-SF)
January 14, 2026
Announcement on Obtaining FDA Implied License for Drug Clinical Trials for DC6001 Tablets by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.
January 12, 2026
Announcement on Wholly-owned Subsidiary Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd. Passing GMP Compliance Inspection
January 7, 2026
Announcement on Completion of Fund Filing for Participating in the Establishment of Double-Crane Pharmaceutical Industry Investment Fund Phase II
January 5, 2026
Announcement on Completion of Fund Filing for the Establishment of Double-Crane Industry Fund
December 30, 2025
Announcement on Hydroxocobalamin Injection Obtaining Notice of Approval for Drug Clinical Trial
December 29, 2025
Announcement on Daily Related Party Transactions
December 26, 2025
Announcement on Notice to Creditors on Repurchasing and Canceling Some Restricted Stocks to Reduce Registered Capital
December 25, 2025
Announcement on Obtaining Approval Notice for Drug Clinical Trials for DC6001 Tablets by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.
December 23, 2025
Notice on Convening the 3rd Extraordinary General Meeting in 2025
December 9, 2025
Announcement on the Inclusion of the Company’s Drug in the National Medical Insurance Catalog
December 8, 2025
Announcement on Wholly-owned Sub-subsidiary Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Passing GMP Compliance Inspection
December 5, 2025
Announcement on Canceling the Board of Supervisors, Amending the Articles of Association and Fully Amending Basic Management Systems
December 3, 2025
Announcement on Holding Subsidiary Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd. Receiving the Drug Supplemental Application Approval for Pioglitazone Hydrochloride Dispersible Tablets
December 1, 2025
Announcement on Wholly-Owned Subsidiary China Resources Saike Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Bisoprolol and Amlodipine Tablets
November 25, 2025
Announcement on Lifting Sales Restrictions and Circulation of Restricted Stocks in 2nd Lifting Period of Reserved Granted Portion under Restricted Stock Incentive Plan of 2021
November 24, 2025
华润双鹤关于控股子公司湖南省湘中制药有限公司奥卡西平片获得药品注册证书的公告
November 18, 2025
Announcement on the Passage of GMP Compliance Inspection by the Company's Holding Subsidiary, Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd.
November 13, 2025
Announcement on Progress in Establishment of Double-Crane Industry Fund and Related Party Transactions
October 29, 2025
Announcement on Progress in Participating in the Establishment of Double-Crane Pharmaceutical Industry Investment Fund Phase II and Related Party Transactions
October 28, 2025
Announcement on Resolutions of the 14th Meeting of the 10th Board of Directors
October 24, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
October 21, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 20, 2025
Announcement on Wholly-owned Subsidiary China Resources Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd. Obtaining the Drug Registration Certificate for Bosentan Dispersible Tablets
September 29, 2025
Announcement on Wholly-Owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Tirofiban Hydrochloride and Sodium Chloride Injection
September 16, 2025
Announcement on the Wholly-Owned Subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. Receiving the Approval Notice for the Supplemental Drug Application of Peritoneal Dialysis Solution (Lactic Acid) Series
September 11, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 9, 2025
Announcement on Resignation of Senior Management Member
September 5, 2025
Announcement on Holding Subsidiary Second Pharma Co., Ltd. Passing GMP Compliance Inspection
September 2, 2025
Announcement on the Receipt of the Drug Supplement Approval Notice for Potassium Chloride Injection by Wholly-Owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd.
August 31, 2025
Announcement on Obtaining Drug Registration Certificate for Some Products by Wholly-owned Subsidiary
August 27, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
August 22, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 20, 2025
Announcement on Establishment of Double-Crane Industry Fund and Related Party Transactions
August 12, 2025
Announcement on the Wholly-Owned Subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. Receiving the Approval Notice for the Supplemental Drug Application of Amino Acid (15) Peritoneal Dialysis Solution
August 1, 2025
Announcement on the FDA Approval for Clinical Trial of DC50292A Tablets by Wholly-owned Sub-subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.
July 29, 2025